IMPACT Therapeutics Inc is a China-based company primarily engaged in the research, development, and commercialization of pharmaceutical products. The Company is principally engaged in the research and development of synthetic lethality-based precision anti-cancer therapies. The Company's product pipeline is primarily composed of Senaparib, as well as novel antibody-drug conjugates (ADCs) and degrader candidates. The Company distributes its products within the domestic market and to overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
06/26/06	HK$12.01	-6.90%	7,24,696
05/26/05	HK$12.90	+6.35%	5,57,159
04/26/04	HK$12.13	+4.57%	5,76,212
03/26/03	HK$11.60	-12.32%	5,69,480
31/26/31	HK$13.23	+14.84%	8,07,400

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

11.10CNY

Average target price

28.52CNY

Spread / Average Target

+156.83%

Consensus

Net sales - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. Other stock markets 01:38:35 06/08/2026 pm IST			5-day change	1st Jan Change
12.01 ^HKD	-6.90%		+0.33%	-

31/07	IMPACT Therapeutics, Inc and Pharmanovia Enter Exclusive License Agreement For Senaparib In Europe, Middle East And North Africa, Australia And New Zealand	CI
28/07	IMPACT Therapeutics, Inc Announces IMP3201 As A Preclinical Candidate, A First-In-Class CEACAM5-Targeted Dual-Payload ADC	CI

Market Cap	285.47Cr 331.67Cr 42Cr 37Cr 34Cr 31Cr 59Cr 4.02TCr 60Cr 401.17Cr 157.46Cr 2.01TCr 158.81Cr 155.31Cr 6.66TCr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	201.24Cr 233.81Cr 30Cr 26Cr 24Cr 22Cr 42Cr 2.83TCr 42Cr 282.8Cr 111Cr 1.42TCr 111.95Cr 109.49Cr 4.7TCr	EV / Sales 2026 *	7x	EV / Sales 2027 *	1.66x
Free-Float	-	Yield 2026 *	-	Yield 2027 *	-

31/07	IMPACT Therapeutics, Inc and Pharmanovia Enter Exclusive License Agreement For Senaparib In Europe, Middle East And North Africa, Australia And New Zealand	CI
28/07	IMPACT Therapeutics, Inc Announces IMP3201 As A Preclinical Candidate, A First-In-Class CEACAM5-Targeted Dual-Payload ADC	CI
27/07	Impact Therapeutics Nominates Preclinical Candidate for GI Cancers	MT
21/07	Impact Therapeutics Announces Clinical Data for Senaparib, IMP4297, and IMP1707 Accepted for Poster Presentation at 2026 ESMO Congress	CI
08/06	Impact Therapeutics Nets HK$120 Million From Full Exercise of IPO Overallotment Option	MT
02/06	Impact Therapeutics, Inc Presents Phase 1/2 Clinical Data for Imp1734 At 2026 Asco Annual Meeting	CI
13/05	Hong Kong Stocks Eke Out Gains; Metis TechBio, Impact Therapeutics Shine on Debut	MT
13/05	Impact Therapeutics Jumps 77% in Hong Kong Trading Debut	MT
13/05	Impact Therapeutics Nets HK$759.5 Million From Hong Kong IPO Ahead of Debut	MT
13/05	IMPACT Therapeutics, Inc has completed an IPO in the amount of HKD 843.7377 million.	CI
12/05	Impact Therapeutics says final offer price under global offering of HK$20.10 per H share	RE
05/05	IMPACT Therapeutics, Inc has filed an IPO in the amount of HKD 913.20964 million.	CI
05/05	IMPACT Therapeutics, Inc Reports Earnings Results for the Full Year Ended December 31, 2025	CI

1 day	-6.90%
1 week	+0.33%
Current month	-9.22%
1 month	-40.31%

IMPACT Therapeutics, Inc Share Price

Stocks

7630

CNE100007LG4

Biotechnology & Medical Research

Valuation: IMPACT Therapeutics, Inc

Chart: IMPACT Therapeutics, Inc

Latest news : IMPACT Therapeutics, Inc

Press Releases: IMPACT Therapeutics, Inc

Quotes and Performance

Course Extremes

Managers and Directors: IMPACT Therapeutics, Inc

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Net sales - Rate of surprise

1 week	11.42	13.5
1 month	10.31	21
Current year	10.31	47.98
1 year	10.31	47.98
3 years	10.31	47.98
5 years	10.31	47.98
10 years	10.31	47.98

Manager	Title	Age	Since
Sui Xiong Cai CEO	Chief Executive Officer	69	01/06/2014
Hui Jun Deng DFI	Director of Finance/CFO	51	01/05/2024
Yan Hua Xu CTO	Chief Tech/Sci/R&D Officer	44	01/01/2025

Director	Title	Age	Since
Ye Tian BRD	Director/Board Member	69	01/06/2014
Sui Xiong Cai BRD	Director/Board Member	69	01/06/2014
Ning Ma BRD	Director/Board Member	44	01/03/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMPACT THERAPEUTICS, INC	-6.90%	+0.33%	-	-	45Cr
LONZA GROUP AG	+0.84%	-0.67%	+3.85%	+15.54%	4.86TCr
REVOLUTION MEDICINES, INC.	+0.98%	+3.43%	+442.05%	+570.61%	4.19TCr
IQVIA HOLDINGS INC.	-2.48%	-3.13%	+29.78%	+5.04%	3.89TCr
BEONE MEDICINES AG	+0.48%	+2.14%	+10.20%	+75.43%	3.72TCr
CELLTRION, INC.	+2.47%	+8.33%	+15.16%	+48.37%	3.07TCr
MEDPACE HOLDINGS, INC.	-1.11%	+0.47%	+35.00%	+123.13%	1.64TCr
ASCENDIS PHARMA A/S	+2.32%	-0.53%	-	-	1.61TCr
EUROFINS SCIENTIFIC SE	+0.69%	+2.27%	+8.61%	+19.48%	1.4TCr
ICON PUBLIC LIMITED COMPANY	-1.74%	-3.12%	+3.18%	-36.25%	1.26TCr
Average	-0.43%	+0.51%	+68.48%	+102.67%	2.57TCr
Weighted average by Cap.	+0.33%	+0.41%	+89.34%	+129.08%

	2026 *	2027 *
Net sales	29Cr 33Cr 4.26Cr 3.69Cr 3.44Cr 3.16Cr 5.97Cr 404.98Cr 6.04Cr 40Cr 16Cr 202.63Cr 16Cr 16Cr 671.1Cr	94Cr 109.36Cr 14Cr 12Cr 11Cr 10Cr 20Cr 1.33TCr 20Cr 132.28Cr 52Cr 663.33Cr 52Cr 51Cr 2.2TCr
Net income	-	-
Net Debt	-84Cr -98Cr -12Cr -11Cr -10Cr -9.26Cr -17Cr -1.19TCr -18Cr -118.37Cr -46Cr -593.59Cr -47Cr -46Cr -1.97TCr	-128.75Cr -149.59Cr -19Cr -17Cr -15Cr -14Cr -27Cr -1.81TCr -27Cr -180.93Cr -71Cr -907.32Cr -72Cr -70Cr -3TCr